Key Highlights

  • Lunai Bioworks (NASDAQ:LNAI) traded at USD 0.26, down 5.45%, in pre-market trading on Tuesday, October 27, 2026, after the company disclosed on Thursday, October 22, 2026 that Nasdaq trading is expected to be suspended on Friday, October 30, 2026.
  • For the fiscal year ended June 30, 2026, revenue was USD 51,992 and net loss was USD 3,562,479, against USD 178,007,489 a year earlier, which included USD 170.4 million of goodwill impairment, per the annual report summary.
  • Nasdaq cited a stockholders' deficit of USD 9,024,946 against a USD 2,500,000 minimum; the board approved voluntary delisting and deregistration, and no hearing will be requested.
  • Pre-market prices are thinly traded and no over-the-counter quotation is planned; the company cannot assure that any trading market will exist after the Nasdaq suspension.

The Pre-Market Move and Its Catalyst

Lunai Bioworks (NASDAQ:LNAI), a company developing AI-enabled discovery platforms, preclinical cell and gene therapy programmes and biodefense tools, traded at USD 0.26, down 5.45%, in pre-market trading on Tuesday, October 27, 2026, according to the pre-market snapshot. The catalyst is the company's release of Thursday, October 22, 2026, which reported a Nasdaq delisting determination. The company stated that it plans to delist voluntarily and deregister and will not request a hearing. It expects Nasdaq trading to be suspended at the opening of business on Friday, October 30, 2026. Delisting is expected on or about Thursday, November 12, 2026. The pre-market decline therefore appears consistent with holders reducing positions before the suspension, which is an inference from the timing.

How the Latest Results Frame the Move

The annual report summary for the fiscal year ended June 30, 2026 shows revenue of USD 51,992, all from one research-services customer. Operating expenses were USD 8,749,925 and the loss from operations was USD 8,697,933. Net loss was USD 3,562,479, helped by a gain of about USD 12.0 million on a bankruptcy and reduced by a loss of USD 7.4 million on debt extinguishment. Cash was USD 1,713,653 at June 30, 2026, the working capital deficit was USD 16,874,093 and the filing carries substantial doubt about continuing as a going concern. As of Tuesday, October 13, 2026, available cash covered less than one month under the current operating plan, so the delisting determination follows directly from the equity shortfall.

Risks and What to Watch

The bull reading rests on the pipeline: a collaboration with BrainStorm Therapeutics signed on Tuesday, August 4, 2026 targets an initial Parkinson's data readout in the first half of 2027, a licence agreement with Tanaist was signed on Tuesday, September 22, 2026 and an NIH STTR grant of USD 1.85 million was cited. The bear reading is that cash is nearly exhausted and the shares will lose their exchange listing. Named risks include liquidity after delisting, the absence of reporting once deregistered and financing needs. The company has also filed a naked short selling lawsuit, the outcome of which is uncertain. Investors should watch trading suspension on Friday, October 30, 2026, delisting on or about Thursday, November 12, 2026 and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Lunai Bioworks (NASDAQ:LNAI) fell 5.45% to USD 0.26 pre-market because the company disclosed on Thursday, October 22, 2026 that Nasdaq trading is expected to be suspended and that it will delist and deregister voluntarily. The key number is the stockholders' deficit of USD 9,024,946 against the USD 2,500,000 minimum. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026, the suspension on Friday, October 30, 2026 and delisting on or about Thursday, November 12, 2026. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.